Translating Molecular Technologies into Routine Newborn Screening Practice

Abstract

by Sarah M. Furnier,Maureen S. Durkin andMei W. Baker
Int. J. Neonatal Screen. 2020, 6(4), 80; https://doi.org/10.3390/ijns6040080 - 15 FEB 2022
Cited by 23 | Viewed by 4054 | Correction
Abstract
As biotechnologies advance and better treatment regimens emerge, there is a trend toward applying more advanced technologies and adding more conditions to the newborn screening (NBS) panel. In the current Recommended Uniform Screening Panel (RUSP), all conditions but one, congenital hypothyroidism, have well-defined genes and inheritance patterns, so it is beneficial to incorporate molecular testing in NBS when it is necessary and appropriate. Indeed, the applications of molecular technologies have taken NBS to previously uncharted territory. In this paper, based on our own program experience and what has been reported in the literature, we describe current practices regarding the applications of molecular technologies in routine NBS practice in the era of genomic and precision medicine. Full article
(This article belongs to the Special Issue Newborn Screening: Promoting Quality to Optimise Benefit and Reduce Harm)
► Show Figures
13 pages, 1233 KiB
Open AccessArticle